Piramal Pharma Limited
Piramal Pharma Limited (PPLPHARMA.NS) Stock Overview
Explore Piramal Pharma Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
188.2B
P/E Ratio
-114.82
EPS (TTM)
$-1.24
ROE
-0.02%
PPLPHARMA.NS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Piramal Pharma Limited (PPLPHARMA.NS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 44.16, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $257.77.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -114.82 and a market capitalization of 188.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.